Company Overview - Bio-Rad Laboratories (BIO) is part of the Medical sector, which includes 1013 individual stocks and currently holds a Zacks Sector Rank of 4 [2] - The Zacks Rank for Bio-Rad Laboratories is 2 (Buy), indicating a positive outlook based on earnings estimates and revisions [3] Performance Metrics - The Zacks Consensus Estimate for Bio-Rad's full-year earnings has increased by 0.7% over the past quarter, reflecting stronger analyst sentiment and an improving earnings outlook [4] - Year-to-date, Bio-Rad has gained approximately 7.5%, outperforming the average return of 5.7% for Medical companies [4] - In the Medical - Products industry, which includes 83 stocks, Bio-Rad is ranked 140 and has slightly underperformed its industry, which has gained an average of 9.8% this year [6] Comparative Analysis - Certara, Inc. (CERT) is another Medical stock that has outperformed the sector with a year-to-date return of 31.3% and a Zacks Rank of 2 (Buy) [5] - Certara belongs to the Medical - Biomedical and Genetics industry, which is ranked 68 and has increased by 4.5% this year [6] Investment Outlook - Both Bio-Rad Laboratories and Certara, Inc. are highlighted as stocks to watch for investors interested in the Medical sector due to their solid performance [7]

Company Overview - Protalix BioTherapeutics, Inc. is a biopharmaceutical company focused on the development, production, and commercialization of recombinant therapeutic proteins using its proprietary ProCellEx® plant cell-based protein expression system [4] - The company is notable for being the first to receive FDA approval for a protein produced through a plant cell-based suspension expression system [4] - Protalix has licensed worldwide development and commercialization rights for taliglucerase alfa, its first product, to Pfizer Inc., while retaining full rights in Brazil [4] Recent Developments - Protalix will present at the 2025 BIO CEO & Investor Conference on February 11, 2025, at 10:15 AM EST [1][2] - The company will provide a corporate overview and participate in one-on-one meetings with registered investors during the conference [2][3] - Protalix's second product, Elfabrio®, received approval from both the FDA and the European Medicines Agency in May 2023 [4] Product Pipeline - Protalix's development pipeline includes proprietary versions of recombinant therapeutic proteins targeting established pharmaceutical markets [5] - Key product candidates include PRX–115, a plant cell-expressed recombinant PEGylated uricase for uncontrolled gout, and PRX–119, a plant cell-expressed long-action DNase I for NETs-related diseases [5]

CHASKA, Minn., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company will participate at the 2025 BIO CEO & Investor Conference. The conference will take place February 10-11, 2025, in New York, NY. Details regarding Lifecore’s participation are as follows: 2025 BIO CEO & Investor ConferenceDetails: Lifecore management, including Paul Josephs, chief executive o ...

Core Insights - Bio-Rad Laboratories, Inc. is experiencing solid momentum in its QX600 Droplet Digital PCR (ddPCR) platform, which is expected to drive growth in upcoming quarters [1] - The clinical diagnostics business is seeing increased demand for quality control products, contributing to overall growth [1] - The company is focusing on international expansion, which is anticipated to yield positive results [1] - However, there are concerns regarding a soft Biopharma segment and macroeconomic pressures affecting Bio-Rad's margins [1] Group 1: Business Performance - Bio-Rad's shares have increased by 13.3% over the past year, outperforming the industry growth of 9.3% and the S&P 500's rise of 25.6% [2] - The company has a market capitalization of $9.57 billion and has consistently surpassed earnings estimates in the last four quarters, with an average surprise of 30.45% [2] - The ddPCR franchise grew in mid-single digits in Q3 2024, supported by additional IP-related royalties and successful market penetration in oncology and cell and gene therapy [5] Group 2: Clinical Diagnostics - The clinical diagnostics segment is experiencing growth, particularly in the diabetes franchise and improvements in immunohematology and quality control businesses [6] - The launch of the IH-500 next instrument aims to enhance system functionality and security, contributing to the competitiveness of the transfusion medicine portfolio [6] - Increased demand for quality control products and favorable comparisons in immunology products have driven growth in the clinical diagnostics group [6] Group 3: International Operations - Bio-Rad operates in over 35 countries outside the United States, with significant international distribution channels [7] - Despite soft market conditions in the Asia-Pacific region, the company remains optimistic about gradual improvements into 2025 [7] - Challenges in key European markets, particularly in Germany and the UK, are expected to be offset by modest improvements in funding outlooks in France and other countries [9] Group 4: Challenges - The Biopharma segment is facing softness, particularly among smaller companies, due to funding constraints in the broader pharmaceutical industry [10] - Demand for process chromatography resins and life science research products has decreased, reflecting an ongoing destocking trend [10] - Bio-Rad's margins are under pressure from inflationary trends, including rising raw material costs, logistics expenses, and higher employee-related costs [11] Group 5: Financial Estimates - The Zacks Consensus Estimate for Bio-Rad's 2024 earnings per share (EPS) has increased by 0.4% to $10.33 in the past 30 days [12] - The estimated revenue for 2024 is projected at $2.57 billion, indicating a 3.7% decline from the previous year [12]

MINNEAPOLIS, Jan. 8, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced it will showcase its new ProPak™ GMP cytokines, alongside its portfolio of innovative products and solutions supporting cell and gene therapy development and manufacturing at Phacilitate's Advanced Therapies Week, taking place January 20-23 at the Kay Bailey Hutchison Convention Center in Dallas, Texas.Bio-Techne will feature its cell and gene therapy workflow reproducibility and scalability solutions, including ...

Core Insights - Bio-Techne Corporation has announced a partnership with MedSanTek to distribute its brands in Turkey, enhancing its market presence in the region [1][3] - MedSanTek is recognized as a leading distributor in in vitro diagnostics and research products, serving Turkey and Azerbaijan, and is known for its high-quality solutions in various scientific fields [2][3] - The partnership aims to leverage MedSanTek's local expertise and Bio-Techne's innovative product portfolio to advance scientific research and healthcare in Turkey and Azerbaijan [3] Company Overview - Bio-Techne Corporation is a global life sciences company that provides innovative tools and bioactive reagents for research and clinical diagnostics, generating approximately $1.2 billion in net sales in fiscal 2024 [4] - The company employs around 3,100 people worldwide and offers a vast portfolio of products that assist in scientific investigations and drug discovery [4]

Core Insights - BIO-key International, Inc. has entered into an agreement with Fiber Food Systems, Inc. to enhance security and operational efficiency in the food service sector through the integration of identity and access management (IAM) solutions [1][2][3] Company Overview - BIO-key specializes in workforce and customer identity and access management solutions, focusing on Identity-Bound Biometrics for secure authentication experiences [1][8] - Fiber Food Systems is dedicated to global food security and innovation in food technology, producing high-demand consumer packaged goods and plant-based proteins [1][9] Transaction Details - BIO-key acquired 5,000,000 shares of Boumarang, Inc. from Fiber in exchange for 595,000 shares of BIO-key, representing 19% of BIO-key's issued shares, strengthening its balance sheet with an additional $5 million in net assets [1] Strategic Collaboration - The partnership aims to combine BIO-key's IAM expertise with Fiber's food technology, enhancing security and streamlining access in high-traffic environments such as schools and universities [2][3] - BIO-key's PortalGuard IAM platform supports over 35 million users with phoneless, tokenless, and passwordless access options, which will be integrated into Fiber's food service operations [2][8] Innovation and Growth Opportunities - The collaboration is expected to improve operational efficiency in time-sensitive food service environments by deploying biometric authentication [4] - BIO-key's scalable IAM solutions will allow Fiber to implement tailored security measures across its expanding food tech and distribution network [5] - The partnership reflects a commitment to innovation in the food tech sector, setting a benchmark for safety and efficiency in food service technology [6] Leadership Statements - The CEO of BIO-key emphasized the importance of delivering secure IAM solutions to industries requiring seamless access, particularly in food services [7] - The Executive Chairperson of Fiber highlighted the alignment of their mission with BIO-key's technology to transform the food tech industry [7]

MINNEAPOLIS, Nov. 27, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman, President and Chief Executive Officer, will present at the Citi 2024 Global Healthcare Conference on Wednesday, December 4, 2024, at 3:15 p.m. EST. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.About Bio-TechneBio-Techne Corporation (NASDAQ: TECH) is a global life sciences ...

MINNEAPOLIS, Nov. 20, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities today announced a partnership with Leader Life Sciences. Under the agreement, Leader Life Sciences becomes a distributor of Bio-Techne's portfolio across the Gulf Cooperation Council (GCC) countries, which include Bahrain, Oman, Qatar, Saudi Arabia, and United Arab Emirates.Founded in 2020, Lead ...

MINNEAPOLIS, Nov. 18, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced a strategic partnership with ALZpath, Inc to accelerate breakthroughs in neurodegenerative disease research and treatment, including Alzheimer's disease. The collaboration leverages Bio-Techne's Ella™ fully automated, multiplexing immunoassay platform and ALZpath's proprietary pTau217 antibody to provide the Simple Plex Human Phospho-Tau (T217) ALZpath Assay. ALZpath The ALZpath pTau217 (phosphorylated Tau2 ...